+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Novocure Cancer Research Grant

Novocure

Additional InformationAdditional details regarding this grant can be found in the Program Guidelines and Application Instructions. Final determinations of eligibility will not be completed until the AACR is in receipt of the submitted application.

Description

The AACR-Novocure Cancer Research Grants represent a joint effort to promote and support independent investigators who are currently conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage independent investigators to enter the TTFields research field.

These grants are intended to provide a deeper understanding of the mechanisms of action of this novel anti-cancer treatment modality and to accelerate the development of new treatment strategies to advance therapeutic options for cancer. The research proposed for funding may be basic or translational in nature; however, studies promoting the transition of in vitro work into in vivo systems, combination therapies involving TTFields, or translational projects bringing treatments involving TTFields into the clinic will be prioritized. The Inovitro® system (which will be provided by Novocure, if needed), must be included in the experimental design. Training on the use of Inovitro® system will be provided by Novocure, if needed. Note that inter-laboratory collaboration is encouraged, particularly for applicants new to TTFields research.

This grant provides $350,000 over three years for expenses related to the research project, which may include salary and benefits of the grant recipient and any collaborators, postdoctoral or clinical research fellows, graduate students and/or research assistants; research/laboratory supplies; equipment; travel; publication charges for manuscripts that pertain directly to the funded project; other research expenses; and indirect costs.

Research Project Criteria

Research proposals must incorporate the Inovitro® and/or inovivo® systems into the experimental design. For grant recipients who are affiliated with institutions that do not currently hold a Materials Transfer Agreement (MTA) with Novocure for use of its devices, Novocure will provide this system to complete the research. For additional details, please see the MTA and Terms and Conditions. If selected for funding, Novocure will work with the institution to execute an MTA.

Research projects should examine the use of TTFields as a therapeutic modality for cancer. Proposals may include 1) Basic and translational approaches, promoting the transition of TTFields in vitro work into in vivo systems, 2) Studies that link preclinical and clinical data, or 3) Studies with ability to translate into the clinic for cancer treatment.

Projects that focus on one or more of the areas outlined below are strongly encouraged, provided they incorporate the use of Inovitro® and/or inovivo® systems:

Key cancer-related signaling and cellular pathways.
Metabolic effects of TTFields.
Studies that include Omics data (genomics, transcriptomics, proteomics).
TTFields immunological aspects and the potential combination with immunotherapy.
Combinational studies with approved agents (preferably to include mechanistic aspects).

AI Based Application Success Predictor

🧠 1. Strong Alignment with TTFields Research (Top Predictor)

Novocure funding is highly focused on:

Tumor Treating Fields (TTFields) mechanism, optimization, or expansion
New indications beyond current approvals (e.g., glioblastoma → lung, pancreatic, ovarian cancers)

👉 Proposals unrelated to TTFields have very low success rates

🎯 2. Clear Clinical or Translational Impact

Successful proposals typically:

Improve clinical outcomes (survival, progression-free survival)
Optimize TTFields usage (dose, duration, combinations)
Address real-world clinical challenges

👉 Pure lab research is less competitive unless clearly translational

🧪 3. Combination Therapy Strategy (Major Advantage)

High success probability if the project explores:

TTFields + chemotherapy
TTFields + immunotherapy
TTFields + radiotherapy

👉 Combination studies are a major strategic priority

🧬 4. Strong Scientific Rationale

Mechanistic understanding of TTFields
Preclinical or pilot data supporting feasibility
Clear biological hypothesis

👉 Weak rationale = frequent rejection

🏥 5. Access to Patient Population & Clinical Infrastructure

Oncology centers with:
- Relevant patient cohorts (especially brain tumors, thoracic cancers)
- Clinical trial capability
Experience with device-based therapies

👩‍⚕️ 6. Investigator Expertise

Background in:
- Neuro-oncology
- Medical oncology
- Radiation oncology
Prior publications or trials in related areas

📊 7. Feasible Study Design

Realistic recruitment timelines
Clearly defined endpoints
Regulatory feasibility

👉 Overly ambitious or complex designs reduce success

🤝 8. Collaboration with Key Oncology Centers

Multicenter studies
Partnerships with established cancer institutes

👉 Collaboration increases credibility and scalability

💰 9. Budget & Resource Justification

Efficient use of funding
Clear linkage between costs and outcomes

📑 10. Compliance & Ethical Considerations

Regulatory approvals
Device usage compliance
Patient safety protocols

📊 Summary: Key Predictors (Ranked)

Highest impact factors:

Alignment with TTFields research
Clinical/translational impact
Combination therapy focus

Moderate predictors:
4. Scientific rationale
5. Investigator expertise
6. Clinical feasibility

Supporting factors:
7. Collaboration
8. Budget clarity
9. Compliance

💡 Insider Insight

Compared to other oncology funders:

👉 Novocure is technology-centric

The key question is:
“Does this expand or optimize TTFields use?”
Projects that:
- Extend TTFields to new cancers
- Combine with emerging therapies
  → have the highest success probability

Specialties

Cancer

Oncology

Eligibility Requirements

At the start of the grant term (December 1, 2026), applicants must:

Have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field.
Be independent investigators. Applicants must hold a faculty position (i.e., professor, assistant professor, research assistant professor, instructor, or equivalent)
- If eligibility is based on a future position, the position must be confirmed at the time of submission and CANNOT be contingent upon receiving this grant. Applicants are advised to contact the AACR’s Research and Grants Administration (RGA) at grants@aacr.org before submission to confirm they will hold an eligible position.
Work at an academic, medical, or research institution anywhere in the world.

At the start of the grant term (December 1, 2026), applicants cannot:

Be a candidate for a further doctoral degree.
Be an employee or subcontractor of a U.S. federal government entity or for-profit private industry. They may serve as collaborators, but no grant funds may be directed toward these individuals.
Be postdoctoral or clinical research fellows (or equivalent) working under the auspices of a scientific mentor. Qualified fellows are invited to apply for an AACR Fellowship.
Be a current or past recipient of an AACR-Novocure Tumor Treating Fields Research Grant. Collaborators or other participants of an active AACR Novocure grant (at the time of application deadline) are also not eligible to apply.
- Current recipients of an AACR-Novocure Career Development Award for Tumor Treating Fields Research Grant may apply if their current grant ends and their final progress reports have been approved before the start of the grant term of this funding opportunity.
Concurrently hold another AACR grant.
- Current AACR grantees may apply only if their current grant ends and their final progress reports have been approved before the start of the grant term for this funding opportunity.

Investigators may submit only one application for this funding opportunity but may concurrently apply for other AACR grants. However, applicants are expected to accept the first grant they are awarded. Individuals may accept and hold only one AACR grant at a time.

Multiple applications for the AACR-Novocure Cancer Research Grant may be submitted from the same institution as long as the applicants are not collaborators on an active Novocure grant.

All applicants with questions about eligibility should contact the AACR’s Research and Grants Administration at grants@aacr.org before submitting an application.

Sponsor Details

Sponsor Institute/Organizations: Novocure

Sponsor Type: Corporate/Non-Profit

Address: 615 Chestnut St., 17th Floor Philadelphia

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity